Droxidopa hydrochloride  (Synonyms: L-DOPS hydrochloride; DOPS hydrochloride; SM5688 hydrochloride)

Droxidopa (L-DOPS) hydrochloride is a potent, orally active norepinephrine precursor. Droxidopa hydrochloride increases standing blood pressure, ameliorates symptoms of orthostatic hypotension and improves standing ability. Droxidopa hydrochloride has the potential for the research of neurogenic orthostatic hypotension (nOH) and alternative ADHD (attention deficit hyperactivity disorder)^[1][2][3][4].

Droxidopa hydrochloride (200 mg/kg;i.p.) alters dopamine neuron and prefrontal cortex activity and improves attention-deficit/hyperactivity disorder-like behaviors in rats^[2]. Droxidopa hydrochloride (10, 20 mg/kg; i.p.) significantly increases the paw withdrawal latency and inhibits mechanical hypersensitivity to thermal stimulation in 6-OHDA-lesioned rats at the 5th week after surgery^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

249.65

C₉H₁₂ClNO₅

1260173-94-1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Horacio Kaufmann, et al. Droxidopa for neurogenic orthostatic hypotension. Neurology, 2014; 83(4).

  [2]. Dela Peña I, et al. Droxidopa alters dopamine neuron and prefrontal cortex activity and improves attention-deficit/hyperactivity disorder-like behaviors in rats. Eur J Pharmacol. 2021 Feb 5;892:173826.  [Content Brief]

  [3]. Cao LF, et al. Restoring Spinal Noradrenergic Inhibitory Tone Attenuates Pain Hypersensitivity in a Rat Model of Parkinson's Disease. Neural Plast. 2016;2016:6383240.  [Content Brief]

  [4]. Kaufmann H. L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience. Clin Auton Res. 2008 Mar;18 Suppl 1:19-24.  [Content Brief]